Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3154207 Capsule, Mevidalen
LY3154207 · 3 trials · 3 indications
iADRS assesses the impact of cognitive loss on everyday activities and provides a measure of global AD severity as a single summary score. It comprises of 2 underlying domains "cognitive ability" and "functional ability," and integrates the items in both the domains a single overall score ranging from 0 to 144, with lower scores indicating worse performance.
The CDR-CCB tests is designed to evaluate the effects of novel compounds on the quality of cognitive functioning which includes tests of attention (simple and choice reaction time, digit vigilance), working memory (spatial and numeric) and episodic memory (word recognition, picture recognition). Continuity of attention measures speed and accuracy and is calculated from 3 attentional tasks on the CDR computerized battery tests. For continuity of attention, the score range is -999 to 35. A high score reflects someone able to keep his/her mind on a single task for a prolonged period. A negative change from baseline reflects impairment compared to baseline. Data presented are model-based bayesian posterior mean response rates with 95% credible interval.
| Arm | Type | Description |
|---|---|---|
| Mevidalen (high dose) | EXPERIMENTAL | Mevidalen high dose administered orally. |
| Mevidalen (low dose) | EXPERIMENTAL | Mevidalen low dose administered orally. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered orally. |
| 10 milligram (mg) LY3154207 | EXPERIMENTAL | Participants received 10 mg LY3154207 administered orally QD. |
| 30 mg LY3154207 | EXPERIMENTAL | Participants received 30 mg LY3154207 administered orally QD. |
| 75 mg LY3154207 | EXPERIMENTAL | Participants received 75 mg LY3154207 administered orally QD. |
| LY3154207 | EXPERIMENTAL | LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days. |
| Name | Type | Description |
|---|---|---|
| Mevidalen | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
| LY3154207 | DRUG | Administered orally. |
Inclusion Criteria: * Have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living. * Have MMSE score of 13 to 24. * Have eligibile plasma P-tau or historical evidence of AD pathology. * Have a relia...
LY3154207 is an investigational small molecule being developed by Eli Lilly and Company for neurological conditions. It has been studied in Lewy body dementia and Parkinson's disease. It is not approved and remains in clinical development.
LY3154207 has been studied for the treatment of dementia due to Lewy body dementia, including dementia associated with idiopathic Parkinson's disease and dementia with Lewy bodies. It is investigational and has not been approved for any indication.
LY3154207 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the clinical trials evaluating the drug in Lewy body dementia and Parkinson's disease.
LY3154207 has completed a Phase 2 clinical trial in Lewy body dementia and a Phase 1 trial in healthy participants and participants with Parkinson's disease. It is an investigational drug and has not been approved by the FDA.
LY3154207 has been evaluated in two completed trials. The Phase 2 trial NCT03305809 enrolled 344 participants with Lewy body dementia across the United States, Canada, and Puerto Rico. The Phase 1 trial NCT02562768 enrolled 80 healthy participants and participants with Parkinson's disease in the United States.
Yes, LY3154207 Capsule is another name for LY3154207. Both refer to the same investigational small molecule developed by Eli Lilly and Company for Lewy body dementia and Parkinson's disease.